BiotechTube

tafamidis meglumine

ApprovedCompleted
0 watching 0 views this week🔥 Hot
84
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Transthyretin Amyloid Polyneuropathy (ATTR-PN)

Conditions

Transthyretin Amyloid Polyneuropathy (ATTR-PN)

Trial Timeline

Apr 28, 2021 → Feb 12, 2023

NCT ID
NCT04828993

About tafamidis meglumine

tafamidis meglumine is a approved stage product being developed by Pfizer for Transthyretin Amyloid Polyneuropathy (ATTR-PN). The current trial status is completed. This product is registered under clinical trial identifier NCT04828993. Target conditions include Transthyretin Amyloid Polyneuropathy (ATTR-PN).

Hype Score Breakdown

Clinical
30
Activity
20
Company
9
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04828993ApprovedCompleted

Competing Products

20 competing products in Transthyretin Amyloid Polyneuropathy (ATTR-PN)

See all competitors
ProductCompanyStageHype Score
Eplontersen Solution for InjectionAstraZenecaPhase 1
33
Eplontersen + PlaceboAstraZenecaPhase 3
77
Treatment of transthyretin (ATTR) amyloidosis in observational study settingAstraZenecaPre-clinical
23
EplontersenAstraZenecaPhase 3
77
Eplontersen + PlaceboAstraZenecaPhase 3
77
NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 3
76
NNC6019-0001Novo NordiskPhase 2
51
NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 2
51
CoramitugNovo NordiskPhase 1
32
TafamidisPfizerPre-clinical
22
TafamidisPfizerPre-clinical
22
Fx-1006APfizerPhase 2
51
TafamidisPfizerPhase 3
76
Tafamidis 61 milligramsPfizerPre-clinical
22
Treatment for TTR amyloidosis + Treatment for TTR amyloidosisPfizerPre-clinical
22
VyndaqelPfizerPre-clinical
22
tafamidisPfizerPhase 3
76
TafamidisPfizerApproved
84
TafamidisPfizerPre-clinical
22
Vyndamax (tafamidis 61mg)PfizerPre-clinical
22

Other Products from Pfizer

MeropenemApproved
84
celecoxibApproved
84
13vPnCApproved
84
EtanerceptApproved
84
AtorvastatinApproved
84